The Association Between the Fluoxetine Use and the Occurrence of Coronary Heart Disease: a Nationwide Retrospective Cohort Study

Overview

Journal BMC Cardiovasc Disord

Publisher Biomed Central

Specialty Cardiology & Vascular Diseases

Date 2024 Nov 10

PMID 39522052

Authors

Fang-Ling Li

Yu-Tse Sheih

Ming-Hsun Lin

Yong-Chen Chen

Wen-Tung Wu

Tsung-Kun Lin

Yu-Ching Chou

Chien-An Sun

Affiliations

Soon will be listed here.

Abstract

Background: We explored if the administration of fluoxetine, recognized for its potential in adipocyte browning, entails a differential risk of coronary heart disease (CHD) in comparison to other SSRI medications.

Methods: Using the National Health Insurance Research Database of Taiwan from 2000 to 2013, we conducted a retrospective cohort study. The exposure cohort comprised individuals prescribed fluoxetine for over 90 days (n = 2,228). Conversely, those administered other SSRIs (excluding fluoxetine) for a duration surpassing 90 days were designated as the non-exposed cohort (n = 8,912). CHD incidence served as our primary outcome measure, and we employed Cox proportional hazards models to scrutinize the relationship between fluoxetine exposure and CHD development rates.

Results: Compared with the non-exposed cohort, the fluoxetine use had a significantly decreased 21% risk of developing CHD in the exposed cohort (adjusted hazard ratio: 0.79%, 95% confidence interval: 0.68-0.92). Noticeably, results indicated that there was an inverse association between the fluoxetine exposure and the risk of CHD, regardless of whether men, women or other age groups.

Conclusion: Our findings suggest that clinical use of fluoxetine was associated with a 21% reduced risk of CHD relative to other SSRI prescriptions.

References

Hsieh C, Su C, Shao S, Sung S, Lin S, Kao Yang Y . Taiwan's National Health Insurance Research Database: past and future. Clin Epidemiol. 2019; 11:349-358. PMC: 6509937. DOI: 10.2147/CLEP.S196293. View

Caiaffo V, Oliveira B, Sa F, Evencio Neto J . Anti-inflammatory, antiapoptotic, and antioxidant activity of fluoxetine. Pharmacol Res Perspect. 2016; 4(3):e00231. PMC: 4876141. DOI: 10.1002/prp2.231. View

Wu C, Chen Y, Ho H, Hsu Y, Kuo K, Wu M . Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection. JAMA. 2012; 308(18):1906-14. DOI: 10.1001/2012.jama.11975. View

Tata L, West J, Smith C, Farrington P, Card T, Smeeth L . General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. Heart. 2005; 91(4):465-71. PMC: 1768803. DOI: 10.1136/hrt.2004.037457. View

Cipriani A, Brambilla P, Furukawa T, Geddes J, Gregis M, Hotopf M . Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev. 2005; (4):CD004185. PMC: 4163961. DOI: 10.1002/14651858.CD004185.pub2. View

Kyriacou D, Lewis R . Confounding by Indication in Clinical Research. JAMA. 2016; 316(17):1818-1819. DOI: 10.1001/jama.2016.16435. View

Scherrer J, Garfield L, Lustman P, Hauptman P, Chrusciel T, Zeringue A . Antidepressant drug compliance: reduced risk of MI and mortality in depressed patients. Am J Med. 2011; 124(4):318-24. DOI: 10.1016/j.amjmed.2010.11.015. View

Sauer W, Berlin J, Kimmel S . Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation. 2003; 108(1):32-6. DOI: 10.1161/01.CIR.0000079172.43229.CD. View

Reid S, Barbui C . Long term treatment of depression with selective serotonin reuptake inhibitors and newer antidepressants. BMJ. 2010; 340:c1468. DOI: 10.1136/bmj.c1468. View

10.

Brunner E, Shipley M, Britton A, Stansfeld S, Heuschmann P, Rudd A . Depressive disorder, coronary heart disease, and stroke: dose-response and reverse causation effects in the Whitehall II cohort study. Eur J Prev Cardiol. 2014; 21(3):340-6. DOI: 10.1177/2047487314520785. View

11.

Donovan M, Tecott L . Serotonin and the regulation of mammalian energy balance. Front Neurosci. 2013; 7:36. PMC: 3608917. DOI: 10.3389/fnins.2013.00036. View

12.

Roth C, Molica F, Kwak B . Browning of White Adipose Tissue as a Therapeutic Tool in the Fight against Atherosclerosis. Metabolites. 2021; 11(5). PMC: 8156962. DOI: 10.3390/metabo11050319. View

13.

Pratt L, Ford D, Crum R, Armenian H, Gallo J, Eaton W . Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation. 1996; 94(12):3123-9. DOI: 10.1161/01.cir.94.12.3123. View

14.

Cheng C, Kao Y, Lin S, Lee C, Lai M . Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf. 2011; 20(3):236-42. DOI: 10.1002/pds.2087. View

15.

Berbee J, Boon M, Khedoe P, Bartelt A, Schlein C, Worthmann A . Brown fat activation reduces hypercholesterolaemia and protects from atherosclerosis development. Nat Commun. 2015; 6:6356. PMC: 4366535. DOI: 10.1038/ncomms7356. View

16.

Hamer M, Batty G, Seldenrijk A, Kivimaki M . Antidepressant medication use and future risk of cardiovascular disease: the Scottish Health Survey. Eur Heart J. 2010; 32(4):437-42. PMC: 3038336. DOI: 10.1093/eurheartj/ehq438. View

17.

Cohen H, GIBSON G, Alderman M . Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med. 2000; 108(1):2-8. DOI: 10.1016/s0002-9343(99)00301-0. View

18.

Braz G, da Silva A, Silva S, Pedroza A, de Lemos M, de Lima F . Chronic serotonin reuptake inhibition uncouples brown fat mitochondria and induces beiging/browning process of white fat in overfed rats. Life Sci. 2020; 245:117307. DOI: 10.1016/j.lfs.2020.117307. View

19.

Kimmel S, Schelleman H, Berlin J, Oslin D, Weinstein R, Kinman J . The effect of selective serotonin re-uptake inhibitors on the risk of myocardial infarction in a cohort of patients with depression. Br J Clin Pharmacol. 2011; 72(3):514-7. PMC: 3175522. DOI: 10.1111/j.1365-2125.2011.04008.x. View

20.

Sauer W, Berlin J, Kimmel S . Selective serotonin reuptake inhibitors and myocardial infarction. Circulation. 2001; 104(16):1894-8. DOI: 10.1161/hc4101.097519. View